Hello . This is Dr Maurie Markman from the Cancer Treatment Centers of America in Philadelphia. I want to briefly discuss the just-released abstracts for the gynecologic cancer session of the upcoming American Society of Clinical Oncology (ASCO) annual meeting.
The oral and poster sessions are going to be very interesting. In these meetings we usually see studies that are focused on chemotherapy. From what I can tell, there are certainly no studies that will change the standard of care in the chemotherapeutic management of ovarian cancer. It is important to note that results of several important phase 3 randomized surgical trials in the malignancy will be presented. One looked at the potential impact of secondary cytoreductive surgery in recurrent disease. A second trial looked at the potential role of hyperthermic intraperitoneal chemotherapy. And a third prospective study looked at the potential role of lymphadenectomy.
There are also long-term follow-up survival data on a number of trials, both in ovarian cancer[4,5] and in endometrial cancer. There are data on checkpoint inhibitor follow-up[7,8,9] and a number of other novel strategies[10,11] being reported at this meeting in the phase 1/early phase 2 setting.
For those interested in new studies and strategies, as well as results of important phase 3 randomized trials, this will be a very interesting meeting with some very interesting sessions. I certainly am looking forward to hearing both the presentations and the discussions.
Thank you for your attention.
Medscape Oncology © 2017 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Advances in Gynecologic Cancer: ASCO 2017 - Medscape - May 26, 2017.